This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves
Merck’s TROP2 ADC delivers a phase III win in endometrial cancer, as new golimumab biosimilars and an oral microbiome therapy move forward
05/26/2026
7 min read
News
